Physician profile
Travis John Roeder
NPI 1396446829
$784.62
in general payments reported to CMS, 2019-2025
10 companies · $196 in 2025
The $196 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $271 · 2024: $318 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $784.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $298.92 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $270.52 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $55.89 | 2024-2025 | Veozah |
| Abbvie INC. | $34.36 | 2024-2025 | |
| Ars Pharmaceuticals Operations, INC. | $27.72 | 2025 | Neffy |
| Kaleo, INC. | $26.85 | 2023 | Auvi-Q |
| Acella Pharmaceuticals, LLC | $20.52 | 2025 | NP Thyroid 60 |
| Otsuka America Pharmaceutical, INC. | $19.52 | 2025 | Rexulti |
| Amgen INC. | $16.45 | 2025 | Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.87 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Roeder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.